

ACORDA THERAPEUTICS INC  
Form 8-K  
January 21, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 21, 2011

Acorda Therapeutics, Inc.  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

000-50513  
(Commission  
File Number)

13-3831168  
(I.R.S. Employer  
Identification No.)

15 Skyline Drive,  
Hawthorne, NY  
(Address of principal  
executive offices)

10532  
(Zip Code)

Registrant's telephone number, including area code: (914) 347-4300

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On January 21, 2011, Acorda Therapeutics, Inc. issued a Statement, posted in the “Investors” and “News & Events” sections of its corporate website ([www.acorda.com](http://www.acorda.com)), regarding the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) decision against approval of FAMPYRA® (prolonged-release fampridine 10 mg tablets) to improve walking ability in adult patients with multiple sclerosis (MS). FAMPYRA is the proposed trade name in Europe for the product commercialized in the U.S. by Acorda Therapeutics under the trade name Ampyra® (dalfampridine) Extended Release Tablets, 10 mg. A copy of the Statement is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference into this Item.

---

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Statement dated January 21, 2011

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Acorda  
Therapeutics, Inc.

January 21, 2011

By: /s/ David  
Lawrence  
Name: David  
Lawrence  
Title: Chief  
Financial Officer

---

Exhibit Index

Exhibit No.	Description
99.1	Statement dated January 21, 2011

---

